Get the Stockscreener App
21.45
0.19%
-0.04
Denali Therapeutics Inc stock is traded at $21.45, with a volume of 2.22M.
It is down -0.19% in the last 24 hours and down -12.16% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$21.49
Open:
$21.36
24h Volume:
2.22M
Relative Volume:
2.71
Market Cap:
$3.09B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-19.68
EPS:
-1.09
Net Cash Flow:
$-402.10M
1W Performance:
-6.62%
1M Performance:
-12.16%
6M Performance:
+0.23%
1Y Performance:
+1.32%
1-Day Range:
$21.00
$22.21
1-Week Range:
$20.76
$24.15
52-Week Range:
$14.56
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8548
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
21.45 | 3.09B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Geode Capital Management LLC Sells 27,061 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Holdings Lifted by Barclays PLC - MarketBeat
Denali Therapeutics upgraded to Buy from Hold at Stifel - Yahoo Finance
Denali Therapeutics Inc. (NASDAQ:DNLI) Position Reduced by Y Intercept Hong Kong Ltd - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Shares Gap UpTime to Buy? - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Upgraded to Buy at Stifel Nicolaus - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $38.90 Average PT from Brokerages - MarketBeat
Nomura Asset Management Co. Ltd. Buys Shares of 65,033 Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
State Street Corp Lowers Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
When (DNLI) Moves Investors should Listen - Stock Traders Daily
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely - Simply Wall St
Point72 Asset Management L.P. Trims Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Wellington Management Group LLP Has $312.49 Million Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Starts Dosing in Phase II Parkinson's Disease Study - MSN
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? - Yahoo Finance
Temasek Holdings Private Ltd Lowers Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Holocene Advisors LP Has $2.84 Million Stake in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
The Manufacturers Life Insurance Company Has $6.03 Million Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Charles Schwab Investment Management Inc. Trims Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics Announces First Participant Dosed in - GlobeNewswire
Denali Therapeutics Launches Key Phase 2a Trial for Breakthrough Parkinson's Treatment - StockTitan
26,900 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Purchased by Erste Asset Management GmbH - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Position Boosted by Cinctive Capital Management LP - MarketBeat
Fmr LLC Purchases 7,596,508 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Wasatch Advisors LP Reduces Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Bought by Fred Alger Management LLC - MarketBeat
Denali Therapeutics Getting Closer To Key Technical Measure - MSN
Algert Global LLC Has $1.42 Million Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
29,543 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Purchased by Intech Investment Management LLC - MarketBeat
Fisher Asset Management LLC Buys 69,223 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
PTC halts development of ALS drug after trial miss - The Pharma Letter
Victory Capital Management Inc. Has $1.16 Million Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Objective long/short (DNLI) Report - Stock Traders Daily
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $38.90 Consensus PT from Analysts - MarketBeat
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging - MSN
Denali Therapeutics updates bylaws, aligns with SEC rules - Investing.com India
Denali Therapeutics updates bylaws, aligns with SEC rules By Investing.com - Investing.com UK
Denali Therapeutics (NASDAQ:DNLI) Trading Down 8.3%Here's What Happened - MarketBeat
Denali Has A Neurodegenerative Edge Despite Market Skepticism (NASDAQ:DNLI) - Seeking Alpha
Los Angeles Capital Management LLC Trims Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
State of New Jersey Common Pension Fund D Sells 25,613 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Capital Research Global Investors Expands Stake in Denali Therap - GuruFocus.com
NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears - GlobeNewswire
FMR LLC Expands Stake in Denali Therapeutics Inc - GuruFocus.com
BofA raises Denali Therapeutics target to $34 on BLA plans By Investing.com - Investing.com Canada
Denali Therapeutics executive sells shares worth $465,286 - Investing.com India
Denali Therapeutics executive sells shares worth $465,286 By Investing.com - Investing.com Canada
Baillie Gifford & Co. Sells 417,709 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Principal Financial Group Inc. Increases Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):